Pritzker School of Medicine

Varsity Healthcare Partners Adds Dr. Pat Basu to Its Senior Leadership Team

Retrieved on: 
Wednesday, February 1, 2023
General Health, Finance, Other Health, Health, Professional Services, MBA, Organization, Pritzker School of Medicine, Presidential Advisory Council on HIV/AIDS, Physician, Champaign–Urbana metropolitan area, Government, Mechanical engineering, Senior advisor, Partner, UnitedHealth Group, Private practice, Patient, Frazier Healthcare Partners, Business, University of Chicago Booth School of Business, University, White House, Culture, Varsity, VHP, Stanford University, White House Fellows, Mechanical, Partnership, Teleradiology, Growth, Doctor of Medicine, Partner (business rank), Management

Varsity Healthcare Partners (“VHP”, “Varsity” or “the Firm”), a lower middle market healthcare services private equity investment firm, today announced the addition of Dr. Pat A. Basu to its leadership team.

Key Points: 
  • Varsity Healthcare Partners (“VHP”, “Varsity” or “the Firm”), a lower middle market healthcare services private equity investment firm, today announced the addition of Dr. Pat A. Basu to its leadership team.
  • Based out of VHP’s Chicago office, Dr. Basu will lead the entirety of VHP’s Operating Partner program in the role of Managing Partner, Varsity Operations, as well as support VHP’s healthcare services investment activities as a Partner and Member of the Firm’s Investment Committee.
  • “Pat Basu has been a world-class leader of growth healthcare services organizations, as well as a skilled operator and developer of physician and executive leaders,” said David Alpern, co-Founder and Managing Partner at Varsity Healthcare Partners.
  • “Beyond his significant career achievements, Pat is a high energy, compassionate leader, who cares deeply about both team and organizational excellence.

Researchers at University of Chicago and Johns Hopkins University to Better Measure Social Determinants of Health: the Social Vulnerability Metric (SVM)

Retrieved on: 
Thursday, January 12, 2023
MPH, Chicago Department of Public Health, COVID, ZCTA, SVM, University of Chicago, Data, University, MIRT, ZIP Code Tabulation Area, Pritzker School of Medicine, COVID-19, Public health, Agency for Healthcare Research and Quality, Health services research, PO, Health care, Human services, Vaccination, Environment, AHRQ, Research, Health, Vaccine, SVI, Johns Hopkins Bloomberg School of Public Health, Social determinants of health, Diabetes, Mortality, Stroke, BA, Federal, Asthma, CDC, Doctor of Philosophy, Chicago (franchise), Agriculture, Pharmaceutical industry, Management, MD

CHICAGO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability. The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective. The SVM can serve as a tool for public health policy and practice, significantly impacting the understanding of an individual's risk based solely on their zip code.

Key Points: 
  • A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability.
  • The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective.
  • CHICAGO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability.
  • The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective.

Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, December 15, 2022
Faculty, Allison, Medical Affairs Bureau, Pritzker School of Medicine, Alpert Medical School, Pregnancy, Chicago (franchise), Paganini Competition, Sirna, Comanche, Patient, Death, Immunization, Disease, Woman, CMV, COVID-19, History, Brown University, Premature, Self-signed certificate, Vaccine, Drug, University, RSV, Mortality, Infant, Health, Harvard Medical School, Bryn Mawr College, Gynaecology, Pharmaceutical industry, Chikungunya, Diagnosis, Pre-eclampsia, Obstetrics, Moderna, Novavax

CONCORD, Mass., Dec. 15, 2022 /PRNewswire/ -- Comanche Biopharma , a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia, today announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the companys Chief Medical Officer.

Key Points: 
  • CONCORD, Mass., Dec. 15, 2022 /PRNewswire/ -- Comanche Biopharma , a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia, today announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the companys Chief Medical Officer.
  • "We are very pleased to have Allison join Comanche.
  • Her academic career included faculty positions at the Brown University Medical School and adjunctive faculty at Harvard Medical School affiliated hospitals.
  • "We are at a unique moment when an effective treatment for preeclampsia may finally be within medical reach," said Johnson.

Doctivity™ Names National Healthcare Leaders to Its Board of Directors and Advisory Board

Retrieved on: 
Tuesday, August 9, 2022
Public relations, New England, CEO, GLOBE, FACS, White House Fellows, Phoenix Children's Hospital, Leadership, Chicago (franchise), Board, Knowledge, Department, Marketing, Executive, PRSA, Public Relations Society of America, Board of directors, Hunting, MD, City, Hunter Group, Industry, Technology, CFRE, Communication, Richard T. Crane, Health, Deaconess, Geisinger Health System, Advisory board, Physician, JD, Hospital, Pritzker School, Patient safety, Senior, APR, Virtua, Pritzker School of Medicine, Harvard Medical School, Director, Society, McDermott, Joint Commission, MPA, Cooper University Hospital, Society for Healthcare Strategy and Market Development, Organization, White House, Associate, PRM, University, Management

BLOOMSBURG, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- - Doctivity announced today the appointment of experienced national healthcare leaders to its Board of Directors and Advisory Board: Michael Loscalzo, Executive Board Chair; Glenn Steele, M.D., Ph.D., Advisory Board Chair; Board of Directors members Adrienne Kirby, Ph.D., FACHE, and Michael Suk, MD, JD, FACS; and Advisory Board member Jean Hitchcock, MPA, APR, CFRE.

Key Points: 
  • BLOOMSBURG, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- - Doctivity announced today the appointment of experienced national healthcare leaders to its Board of Directors and Advisory Board: Michael Loscalzo, Executive Board Chair; Glenn Steele, M.D., Ph.D., Advisory Board Chair; Board of Directors members Adrienne Kirby, Ph.D., FACHE, and Michael Suk, MD, JD, FACS; and Advisory Board member Jean Hitchcock, MPA, APR, CFRE.
  • "The depth of knowledge and accomplishment of our new board members is incredible and inspiring," said Cathryn Connolley-Kluck, Doctivity President and Chief Operating Officer.
  • In addition, Steele is Chairman of the Board of City of Hope world-renowned cancer and diabetes research and treatment organization.
  • Doctivity software was built by seasoned industry executives to deliver strategic growth opportunities for top-line revenue growth.

Psychologist and Author Reveals How Hospitals Can Ease Their Morale Issues

Retrieved on: 
Tuesday, July 26, 2022
Publishing, University, Tree of life, Health, FAAFP, Morale, Hospital, Hospitality Review, Research, 1, Language, COVID-19, Multimedia, Pritzker School of Medicine, Organization, Leadership, Life, Amazon, Healer, Interior design, Management, Medicine

WINSTON-SALEM, N.C., July 26, 2022 /PRNewswire/ -- According to the trade publication Becker's Hospital Review, hospitals across the U.S. are facing workforce shortages, some so severe that they have had to scale back on the services they offer. This is not surprising given that 22 million U.S. healthcare professionals and another 38 million around the world had nearly every aspect of their lives negatively impacted by the COVID-19 pandemic. 

Key Points: 
  • This is not surprising given that 22 million U.S. healthcare professionals and another 38 million around the world had nearly every aspect of their lives negatively impacted by the COVID-19 pandemic.
  • But, as Katherine Kelly, Ph.D., M.S.P.H, says, making them whole again will require more than offering higher wages and signing bonuses.
  • During her research she realized that it wasn't just the "soul" of healthcare workers that was impacted, it was the "soul" of healthcare itself.
  • "Like individuals, healthcare organizations are struggling because they've lost touch with who they are.

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

Retrieved on: 
Thursday, June 23, 2022
ACT, Department, Regulation of tobacco by the U.S. Food and Drug Administration, Diabetic retinopathy, Director, Forward-looking statement, University, Board of directors, GLOBE, Therapy, Annual report, Harvard Medical School, CEO, Champaign–Urbana metropolitan area, Private Securities Litigation Reform Act, Hans-Olov Adami, IgG4-related ophthalmic disease, NASDAQ, News, SEC, Nasdaq, Visual acuity, Champaign County, Illinois, Board, VEGF, OSI Pharmaceuticals, Â, FDA, COVID-19, Human Development Innovation Fund, Patient, Toxic epidermal necrolysis, U.S. FDA, Eye, Senior, Șaeș, Company, AMD, Research, THE, Chicago (franchise), Food, Pritzker School of Medicine, Pharmaceutical industry, Biology, Ophthalmology

It is my pleasure to welcome Dr. Adamis to EyePoints Board of Directors, said Dr. Gran Ando, M.D., Chair of the Board of EyePoint Pharmaceuticals.

Key Points: 
  • It is my pleasure to welcome Dr. Adamis to EyePoints Board of Directors, said Dr. Gran Ando, M.D., Chair of the Board of EyePoint Pharmaceuticals.
  • On behalf of the Board of Directors, we are excited to have Tonys expertise and look forward to collaborating with him.
  • Dr. Adamis was elected to the Board of Directors by the Companys shareholders at the Companys annual meeting held earlier today, along with a slate of returning directors.
  • EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Retrieved on: 
Wednesday, June 1, 2022
UCLA, CVS Caremark, Pritzker School, Research, Cedars-Sinai Medical Center, Biotechnology, Knowledge, Keck School of Medicine of USC, USC, ADA, Pressure, Legislation, Forward-looking statement, Coronavirus Scientific Advisory Board (Turkey), Security (finance), Guideline, U.S. Securities and Exchange Commission, Diabetes, Public service, Nasdaq, University, TASE, Method, FDA, Endocrinology, POD, Technology, Book, MD, Bernardo Houssay Award, Stanford University, Pritzker School of Medicine, Chicago (franchise), Pharmaceutical industry, Medicine, Oramed, Exercise

NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.

Key Points: 
  • NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
  • Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs.
  • "We are excited to welcome Anne as a new member of Oramed's Scientific Advisory Board.
  • "I am honored to be joining the Scientific Advisory Board of Oramed Pharmaceuticals.

Immunovant to Host Virtual R&D Day on March 30, 2022

Retrieved on: 
Monday, March 28, 2022
Graves' ophthalmopathy, Company, Medicine, Pritzker School of Medicine, FC, Private Securities Litigation Reform Act, Degenerative disease, Myasthenia gravis, Chicago (franchise), Royal College of Pathologists, NIHR, Malignancy, Blood transfusion, SEC, Royal Cornwall Hospitals NHS Trust, U.S. Securities and Exchange Commission, Security (finance), MD, Immunoglobulin G, Technology, Safety, Atorvastatin, Inflammation, Nasdaq, COVID-19, GLOBE, Professor, Annual report, University, Patient, Disease, Bachelor of Science, Antibody, Pharmaceutical industry, Neonatal Fc receptor

To attend the event, please register at: Immunovant R&D Day Registration .

Key Points: 
  • To attend the event, please register at: Immunovant R&D Day Registration .
  • A replay of the event will be available on the Immunovant website following its conclusion.
  • All forward-looking statements are based on estimates and assumptions by Immunovants management that, although Immunovant believes to be reasonable, are inherently uncertain.
  • Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Steven L. Haddad, MD, Joins Extremity Medical as Chief Clinical Officer

Retrieved on: 
Monday, March 14, 2022
Medical Devices, Health, Industry, Foot, Faculty, American Academy, University, William H. Harris (orthopaedic surgeon), Pritzker School of Medicine, Book, Elective surgery, LLC, American Academy of Orthopaedic Surgeons, MD, Feinberg School of Medicine, Georgetown University, Johns Hopkins University, Patient, CME, Solution, American Orthopaedic Foot and Ankle Society, Medical school, Orthopedic surgery, MedStar Union Memorial Hospital, Medical device, Dentistry, Northwestern, Medicine

Extremity Medical, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, today announced Steven L. Haddad, MD has joined Extremity Medical as Chief Clinical Officer.

Key Points: 
  • Extremity Medical, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, today announced Steven L. Haddad, MD has joined Extremity Medical as Chief Clinical Officer.
  • In his new role Dr. Haddad will oversee the development of the product/technology portfolio as well as new medical education courses and clinical studies.
  • He is also an educator and researcher that has participated in numerous clinical and basic science research studies.
  • Extremity Medical, LLC, ( www.ExtremityMedical.com ) founded in 2008, is a privately-held medical device company based in Parsippany, NJ, known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation.

Marathon Health Expands Board of Directors

Retrieved on: 
Tuesday, February 8, 2022
Board of directors, NASDAQ, Motivation, CFO, McDermott, General Atlantic, Marathon, Growth, Department, CO, Multimedia, Division, UnitedHealth Group, Board, Harvard Medical School, University of Chicago, Mental health, Biology, Dean, Geisinger Health System, Health, Student, Pritzker School, Castlight Health, Pritzker School of Medicine, Technology, Patient, Service, University, Founder, CEO, Virtual CFO, Health care, Entrepreneurship, Deaconess, Medical Affairs Bureau, Richard T. Crane, Google, MD, New England, NGM, Health insurance, Medicine, Management, KLAS

INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ --Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model.

Key Points: 
  • INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ --Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model.
  • I'm confident that the contributions of these new Directors will help drive strong and tangible benefits to our ambassadors and the patients that we serve," says Jerry Ford, Marathon Health Board Chairman.
  • The four new Directors join Mr. Jerry Ford, former CEO of Marathon Health; Mr. Robbert Vorhoff, Managing Director and Global Head of Healthcare at General Atlantic; Mr. Jon Michael Reese, Vice President at General Atlantic; Mr. Ben Evans, Co-Founder and Chief Growth & Strategy Officer at Marathon Health; and Mr. Jeff Wells, MD, CEO & Co-Founder of Marathon Health.
  • Marathon Health was named Best in KLAS in 2020 and again in 2021 for its excellence in Worksite Health Services.